246
Participants
Start Date
March 22, 2023
Primary Completion Date
May 2, 2024
Study Completion Date
May 2, 2024
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
placebo
matching placebo
CenExel IResearch, LLC - Decatur, Decatur
Sky Clinical Research Network Group P.C., Atlanta
CenExel iResearch, LLC, Savannah
Clinical Neuroscience Solutions - Jacksonville, Jacksonville
Accel Research Sites - Maitland, Maitland
CNS Healthcare - Orlando, Orlando
South Florida Research Phase I-IV INC, Miami Springs
Accel Research Sites - Lakeland, Lakeland
Clinical Neuroscience Solutions--Memphis, Memphis
Alivation Research, LLC, Lincoln
DelRicht Research - Touro Medical Center, New Orleans
Preferred Research Partners (PRP), Little Rock
Boeson Research, Missoula
AIM Trials, Plano
Houston Clinical Trials, Bellaire
Flourish Research, San Antonio
IMMUNOe International Research Center, Centennial
St Charles Psychiatric Associates & Midwest Research Group, Saint Charles
Center for Psychiatry and Behavioral Medicine Inc, Las Vegas
Advanced Research Center (ARC), Anaheim
Collaborators (2)
Premier Research Group plc
UNKNOWN
Prometrika, LLC
INDUSTRY
Almac
INDUSTRY
Corium, Inc.
INDUSTRY